Bortezomib
2010
Bortezomib: A Drug Review
publication
Evidence: moderate
Author Information
Author(s): Rajappa Senthil
Primary Institution: Indo American Cancer Hospital and Research Institute
Conclusion
Bortezomib is effective in treating multiple myeloma and relapsed mantle cell lymphoma but has significant side effects.
Supporting Evidence
- Bortezomib is a reversible inhibitor of the 26S proteasome, which helps in degrading proteins.
- It is indicated for multiple myeloma and relapsed mantle cell lymphoma.
- Common side effects include peripheral neuropathy, thrombocytopenia, and diarrhea.
- Patients with baseline symptoms are at a greater risk of developing severe neuropathy.
- Thrombocytopenia occurs with a median 60% decrease in platelet count.
- Bortezomib is contraindicated in pregnancy and lactation.
Takeaway
Bortezomib is a medicine that helps treat certain types of blood cancer, but it can cause some serious side effects like nerve pain and low blood platelets.
Methodology
The drug is administered as a slow IV push at a dose of 1.3 mg/m2 on specific days every 3 weeks.
Limitations
The review does not provide specific clinical trial data or detailed statistical analysis.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website